Medically reviewed by Drugs.com. Last updated on Jul 24, 2019.
(et a NER sept)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Auto-injector, Subcutaneous [preservative free]:
Enbrel SureClick: 50 mg/mL (0.98 mL, 1 mL)
Solution Cartridge, Subcutaneous [preservative free]:
Enbrel Mini: 50 mg/mL (0.98 mL, 1 mL)
Solution Prefilled Syringe, Subcutaneous [preservative free]:
Enbrel: 25 mg/0.5 mL (0.5 mL, 0.51 mL); 50 mg/mL (0.98 mL, 1 mL)
Solution Reconstituted, Subcutaneous:
Enbrel: 25 mg (1 ea) [contains benzyl alcohol]
Brand Names: U.S.
- Enbrel Mini
- Enbrel SureClick
- Antirheumatic, Disease Modifying
- Tumor Necrosis Factor (TNF) Blocking Agent
Etanercept is a recombinant DNA-derived protein composed of tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept binds tumor necrosis factor (TNF) and blocks its interaction with cell surface receptors. TNF plays an important role in the inflammatory processes and the resulting joint pathology of rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), and plaque psoriasis.
Absorbed slowly after SubQ injection
Clearance: Children and Adolescents 4 to 17 years: 46 mL/hour/m2 (Enbrel prescribing information 1998); Adults: 160 ± 80 mL/hour
Onset of Action
~2 to 3 weeks; RA: 1 to 2 weeks; Maximum effect: RA: Full effect is usually seen within 3 months
Time to Peak
RA: SubQ: 69 ± 34 hours
Half-life elimination: SubQ: Children ≥4 years and Adolescents (JIA): Mean range: 70 to 94.8 hours (range: 31.2 to 104.8 hours) (Yim 2005); Adults (RA): 102 ± 30 hours
Use: Labeled Indications
Ankylosing spondylitis: Reducing signs and symptoms in patients with active ankylosing spondylitis.
Plaque psoriasis (Enbrel): Treatment of patients ≥4 years of age with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Polyarticular juvenile idiopathic arthritis: Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ≥2 years of age.
Psoriatic arthritis (Enbrel): Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. Etanercept can be used with or without methotrexate.
Rheumatoid arthritis: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Etanercept can be initiated in combination with methotrexate or used alone.
Off Label Uses
Initial data suggest that etanercept may have some benefit in patients suffering from pyoderma gangrenosum. However, some case reports have shown no benefit of using etanercept in pyoderma gangrenosum treatment. Controlled trials are needed to fully assess the efficacy of etanercept in pyoderma gangrenosum [Charles 2007], [Goldenberg 2005], [Roy 2006].
Additional Off-Label Uses
Graft-versus-host disease (treatment)
Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to etanercept or any component of the formulation; patients at risk of sepsis syndrome (eg, immunocompromised, HIV positive)
Note: Erelzi is approved as biosimilar to Enbrel.
Ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis: SubQ: Note: May continue methotrexate, glucocorticoids, salicylates, NSAIDs, or analgesics during etanercept therapy.
Once-weekly dosing: 50 mg once weekly; maximum dose (rheumatoid arthritis): 50 mg/week.
Twice-weekly dosing (off-label dose): 25 mg twice weekly (Bathon 2000; Calin 2004; Davis 2003; Genovese 2002; Mease 2000; Mease 2004)
Plaque psoriasis: SubQ:
Initial: 50 mg twice weekly for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully)
Maintenance dose: 50 mg once weekly
Acute graft-versus-host disease (GVHD), treatment (off-label use): SubQ: 0.4 mg/kg (maximum: 25 mg/dose) twice weekly for 8 weeks (in combination with methylprednisolone) (Levine 2008)
Refer to adult dosing.
Note: Erelzi (etanercept-szzs) is approved as a biosimilar to Enbrel. Approved uses for biosimilar agents may vary (consult product labeling).
Juvenile idiopathic arthritis: Children ≥2 years and Adolescents:
Weight <63 kg: Enbrel: SubQ: 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose. Note: Although FDA approved in patients ≥2 years of age, Erelzi does not have a dosage form that would allow for dosing in patients <63 kg.
Weight ≥63 kg: Enbrel, Erelzi: SubQ: 50 mg once weekly
Twice-weekly dosing: SubQ: 0.4 mg/kg/dose twice weekly, given 72 to 96 hours apart; maximum dose: 25 mg/dose (Lovell 2006); Note: Trials performed with Enbrel product.
Kawasaki disease; acute, adjunct therapy: Limited data available (AHA [McCrindle 2017]): Infants ≥6 months and Children <6 years: SubQ: 0.8 mg/kg/dose for 3 doses; administer first dose within 24 hours after completion of IV immunoglobulin (day 0), the second dose at day 7, and third dose at day 14; maximum dose: 50 mg/dose. Dosing based on an open-labeled pilot trial of 15 pediatric patients (mean age: 2.6 years); all patients also received standard aspirin therapy; no patients required retreatment or rescue therapy for signs/symptoms of Kawasaki disease (Choueiter 2010). A large double-blind, placebo-controlled trial is ongoing [EATAK trial (NCT00841789)] utilizing the same dosage regimen; results pending (Portman 2011). Note: Trials performed with Enbrel product.
Mediterranean fever; familial (FMF) (intolerance or resistance to colchicine): Very limited data available; efficacy results variable: Children ≥11 years and Adolescents: SubQ: 0.8 mg/kg once weekly; maximum dose: 50 mg/dose; dosing based on a case series (n=3); results showed fewer attacks with treatment, median duration of therapy was 3 months and all patients continued colchicine therapy if able; over time, therapy was eventually changed to anakinra due to clinician determined unsatisfactory response (Akgul 2012; Özen 2011; Sakallioglu 2006; Soriano 2013); a case series in adult patients (n=5, age range: 20 to 40 years) reported no further attacks (80%) or decrease frequency (20%) with etanercept (25 mg twice weekly) therapy (Bilgen 2011). Note: Studies performed with Enbrel product.
Children and Adolescents 4 to 17 years Enbrel: SubQ: 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose; results of a long-term study (264 weeks) showed efficacy maintained and therapy generally well-tolerated (Paller 2008; Paller 2010; Paller 2016; Siegfried 2010); Note: Studies performed with Enbrel product.
Adolescents ≥18 years: Enbrel: SubQ: Initial: 50 mg twice weekly administered 72 to 96 hours apart for 3 months; Note: Initial doses of 25 mg or 50 mg per week were also shown to be efficacious; maintenance dose: 50 mg once weekly
Psoriatic arthritis: Adolescents ≥18 years: Enbrel:
Once-weekly dosing: SubQ: 50 mg once weekly
Twice-weekly dosing: SubQ: 25 mg twice weekly (individual doses should be separated by 72 to 96 hours) (Mease 2000; Mease 2004)
Rheumatoid arthritis, ankylosing spondylitis: Adolescents ≥18 years: Enbrel, Erelzi:
Once-weekly dosing: SubQ: 50 mg once weekly
Twice-weekly dosing: SubQ: 25 mg twice weekly (individual doses should be separated by 72 to 96 hours) (Bathon 2000; Calin 2004; Davis 2003; Genovese 2002)
Enbrel: Reconstitute lyophilized powder with 1 mL sterile bacteriostatic water for injection (supplied). Swirl gently, do not shake (some foaming is normal); dissolution takes <10 minutes. Use vial adaptor (supplied) when reconstituting (do not use adaptor if multiple doses are to be withdrawn). If the vial is used for multiple doses, use a 25-gauge needle for reconstituting and withdrawing of solution; use a 27-gauge needle for injection. Do not filter reconstituted solution during preparation or administration.
SubQ: Administer subcutaneously. Rotate injection sites; may inject into the thigh (preferred), abdomen (avoiding the 2-inch area around the navel), or outer areas of upper arm. New injections should be given at least 1 inch from an old site and never into areas where the skin is tender, bruised, red, or hard; any raised thick, red, or scaly skin patches or lesions; or areas with scars or stretch marks. For a more comfortable injection, allow autoinjectors, prefilled syringes, and dose trays to reach room temperature for 15 to 30 minutes (≥30 minutes for autoinjector) prior to injection; do not remove the needle cover while allowing product to reach room temperature. There may be small white particles of protein in the solution; this is not unusual for proteinaceous solutions. Note: If the health care provider determines that it is appropriate, patients may self-inject after proper training in injection technique.
Refrigerate at 2°C to 8°C (36°F to 46°F). Do not shake. Do not freeze or store in extreme heat or cold. Store in the original carton to protect from light or physical damage.
Individual autoinjectors, prefilled syringes, dose trays (containing multi-use vials and diluent syringes), or prefilled pens may be stored between 20°C and 25°C (68°F and 77°F) for a maximum single period of 14 days (Enbrel), 28 days (Erelzi), or 60 days (Brenzys [Canadian product]) with protection from light and sources of heat and humidity. Once an autoinjector, prefilled syringe, dose tray, or prefilled pen has been stored at room temperature, it should not be placed back into the refrigerator; discard after 14 days (Enbrel), 28 days (Erelzi), or 60 days (Brenzys [Canadian product]).
Once the multi-use vial has been reconstituted, use the reconstituted solution immediately or refrigerate at 2°C to 8°C (36°F to 46°F); do not store at room temperature. Reconstituted solution must be discarded after 14 days.
Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. Avoid combination
Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. Avoid combination
BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Avoid combination
Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Avoid combination
Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. Avoid combination
Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. Avoid combination
Cladribine: May enhance the immunosuppressive effect of Immunosuppressants. Avoid combination
Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Monitor therapy
Cyclophosphamide: Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present. Avoid combination
Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Monitor therapy
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Consider therapy modification
Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Consider therapy modification
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Consider therapy modification
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Avoid combination
Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Consider therapy modification
Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Monitor therapy
Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. Monitor therapy
Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. Avoid combination
Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Consider therapy modification
Siponimod: Immunosuppressants may enhance the immunosuppressive effect of Siponimod. Monitor therapy
Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Management: Evaluate patients to see if it is medically appropriate to reduce or discontinue therapy with immunosuppressants prior to initiating sipuleucel-T therapy. Consider therapy modification
Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. Monitor therapy
Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. Monitor therapy
Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents. Avoid combination
Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Monitor therapy
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Consider therapy modification
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Avoid combination
Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. Avoid combination
Dermatologic: Skin rash (3% to 13%)
Gastrointestinal: Diarrhea (3% to 16%)
Infection: Infection (50% to 81%)
Local: Injection site reaction (adults: 15% to 43%; children: 7%; bleeding, bruising, erythema, itching, pain, or swelling; mild to moderate and usually decreases with subsequent injections)
Respiratory: Upper respiratory tract infection (38% to 65%), respiratory tract infection (21% to 54%)
Miscellaneous: Antibody development (non-neutralizing; 4% to 16%), positive ANA titer (11%)
1% to 10%:
Dermatologic: Pruritus (2% to 5%), urticaria ( 2%)
Hypersensitivity: Hypersensitivity reaction (1%)
Miscellaneous: Fever (2% to 3%)
Frequency not defined:
Infection: Abscess, influenza, sepsis
Neuromuscular & skeletal: Osteomyelitis, septic arthritis
Respiratory: Bronchitis, pneumonia, sinusitis
<1%, postmarketing, and/or case reports: Anemia, angioedema, aplastic anemia, aseptic meningitis, aspergillosis, autoimmune hepatitis, cardiac failure, chest pain, cutaneous lupus erythematous, demyelinating disease of the central nervous system, erythema multiforme, fungal infection (including histoplasmosis), Guillain-Barré syndrome, hepatotoxicity (idiosyncratic) (Chalasani 2014), herpes zoster, increased serum transaminases, inflammatory bowel disease, interstitial pulmonary disease, leukemia, leukopenia, lupus-like syndrome, lymphadenopathy, malignant lymphoma, malignant melanoma, malignant neoplasm, Merkel cell carcinoma, multiple sclerosis, neutropenia, optic neuritis, pancytopenia, paresthesia, pneumonia due to Pneumocystis carinii, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), reactivation of HBV, sarcoidosis, scleritis, seizure, skin carcinoma, Stevens-Johnson syndrome, subcutaneous nodule, thrombocytopenia, toxic epidermal necrolysis, transverse myelitis, tuberculosis (including pulmonary and extrapulmonary), uveitis, varicella zoster infection, vasculitis (cutaneous and systemic)
ALERT: U.S. Boxed WarningSerious infections:
Patients treated with etanercept are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients treated with etanercept who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.
Discontinue etanercept if a patient develops a serious infection or sepsis.
Reported infections include the following:
Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before etanercept use and during therapy. Initiate treatment for latent infection prior to etanercept use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.
Carefully consider the risks and benefits of treatment with etanercept prior to initiating therapy in patients with long-term or recurrent infections.
Closely monitor patients for the development of signs and symptoms of infection during and after treatment with etanercept, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.Malignancies:
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept.
Concerns related to adverse effects:
• Anaphylaxis/hypersensitivity reactions: Allergic reactions may occur, if an anaphylactic reaction or other serious allergic reaction occurs, administration should be discontinued immediately and appropriate therapy initiated.
• Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome or autoimmune hepatitis, have been reported; monitor and discontinue if symptoms develop.
• Demyelinating CNS disease: Rare cases of new-onset or exacerbation of CNS demyelinating disorders have occurred; may present with mental status changes and some may be associated with permanent disability. Optic neuritis, transverse myelitis, multiple sclerosis, Guillain-Barré syndrome, and other peripheral demyelinating neuropathies have been reported. Use with caution in patients with preexisting or recent-onset CNS demyelinating disorders.
• Heart failure: Worsening and new-onset heart failure has been reported, including in patients without known preexisting cardiovascular disease. Use with caution in patients with heart failure or decreased left ventricular function. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).
• Hematologic disorders: Rare cases of pancytopenia and aplastic anemia have been reported (some fatal). Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with a history of significant hematologic abnormalities.
• Hepatitis B: Rare reactivation of hepatitis B (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants (has been fatal); evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; consider interruption of therapy if reactivation occurs and treat appropriately with antiviral therapy. If resumption of therapy is deemed necessary, exercise caution and monitor patient closely.
• Infections: [US Boxed Warning]: Patients receiving etanercept are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate, corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (including reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral, or other opportunistic infections (including Legionellosis and Listeriosis) have been reported. Monitor closely for signs/symptoms of infection during and after treatment. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to initiating therapy in patients with chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infections who develop severe systemic illness. Caution should be exercised when considering use in elderly patients, patients with chronic or recurrent infections, patients exposed to tuberculosis, patients with a history of an opportunistic infection, in patients with conditions that predispose them to infections (eg, advanced or poorly controlled diabetes), residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent infections. Do not initiate etanercept therapy in patients with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.
• Malignancy: [US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescents receiving TNF-blocking agents, including etanercept. Half of the malignancies reported in children and adolescents were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. The impact of etanercept on the development and course of malignancy is not fully defined. Compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma and leukemia. Lymphomas and other malignancies were also observed (at rates higher than expected for the general population) in adult patients receiving etanercept. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn disease or ulcerative colitis. Melanoma, nonmelanoma skin cancer, and Merkel cell carcinoma have been reported. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk of skin cancer.
• Tuberculosis: [US Boxed Warning]: Active tuberculosis (disseminated or extrapulmonary), including reactivation of latent tuberculosis, has been reported in patients receiving etanercept. Evaluate patients for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to and during therapy. Treatment for latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis during and after treatment. Consider antituberculosis treatment if an adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or with risk factors despite negative skin test. Some patients who tested negative prior to therapy have developed active infection; tests for latent tuberculosis infection may be falsely negative while on etanercept therapy. Use with caution in patients who have traveled to or resided in regions where tuberculosis is endemic. Monitor for signs and symptoms of tuberculosis in all patients.
• Alcoholic hepatitis: Use with caution in patients with moderate to severe alcoholic hepatitis. Compared to placebo, the mortality rate in patients treated with etanercept was similar at one month but significantly higher after 6 months.
• Seizure disorders: Use with caution in patients with a history of seizures; new-onset or exacerbation of seizures have been reported.
• Wegener granulomatosis: Use is not recommended in patients with Wegener granulomatosis who are receiving immunosuppressive therapy due to higher incidence of noncutaneous solid malignancies.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Elderly: Infection has been reported at a higher incidence; use caution in elderly patients.
• Pediatric: Malignancies have been reported among children and adolescents.
• Varicella virus exposure: Patients with a significant exposure to varicella virus should temporarily discontinue therapy; treatment with varicella zoster immune globulin should be considered.
Dosage form specific issues:
• Benzyl alcohol and derivatives: Diluent for injection may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.
• Latex: Some dosage forms may contain dry natural rubber (latex).
• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.
Monitor improvement of symptoms and physical function assessments. Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).
Adverse events have not been observed in animal reproduction studies. Etanercept crosses the placenta. Following in utero exposure, concentrations in the newborn at delivery are 3% to 32% of the maternal serum concentration.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience injection site irritation, headache, diarrhea, or common cold symptoms. Have patient report immediately to prescriber signs of infection, signs of aplastic anemia (fever, pharyngitis, mouth sores, infections, bruising, or purple skin splotches), signs of lupus (rash on the cheeks or other body parts, sunburn easy, muscle or joint pain, angina or shortness of breath, or swelling in the arms or legs), signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), signs of heart problems (cough or shortness of breath that is new or worse, swelling of the ankles or legs, abnormal heartbeat, weight gain of more than five pounds in 24 hours, dizziness, or passing out), burning or numbness feeling, severe weakness, seizures, vision changes, dizziness, pale skin, eczema, swollen glands, night sweats, shortness of breath, unintentional weight loss, skin growths or lumps, skin changes, or mole changes (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about etanercept
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 261 Reviews
- Drug class: antirheumatics
- FDA Alerts (4)
Other brands: Enbrel